- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- 22 Sep 23 424B3 Prospectus supplement
- 21 Sep 23 424B3 Prospectus supplement
- 15 Aug 23 EFFECT Notice of effectiveness
- 14 Aug 23 424B3 Prospectus supplement
- 10 Aug 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 4 Aug 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 17 Jul 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 26 Jun 23 S-4/A Registration of securities issued in business combination transactions (amended)
-
15 May 23 S-4 Registration of securities issued in business combination transactions
- 4 Aug 23 Registration of securities issued in business combination transactions (amended)
- 17 Jul 23 Registration of securities issued in business combination transactions (amended)
- 26 Jun 23 Registration of securities issued in business combination transactions (amended)
- 15 May 23 Registration of securities issued in business combination transactions
Exhibit 99.2
Consent to be Named as a Director Nominee
In connection with the filing by GRAF Acquisition Corp. IV of the Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of GRAF Acquisition Corp. IV (which will be renamed NKGen Biotech, Inc.) following the consummation of the business combination in the Registration Statement and any and all amendments and supplements thereto. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.
Date: May 15, 2023 |
| /s/ Sangwoo Park |
Sangwoo Park |